Liposomal amphotericin B associated with severe hyperphosphatemia

Pediatr Infect Dis J. 2008 Jan;27(1):77-9. doi: 10.1097/INF.0b013e31815922a3.

Abstract

We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Amphotericin B / adverse effects*
  • Amphotericin B / therapeutic use
  • Child
  • Drug Combinations
  • Female
  • Humans
  • Hyperphosphatemia*
  • Male
  • Mycoses / drug therapy*
  • Phosphatidylcholines / therapeutic use
  • Phosphatidylglycerols / therapeutic use
  • Renal Insufficiency / complications

Substances

  • Drug Combinations
  • Phosphatidylcholines
  • Phosphatidylglycerols
  • liposomal amphotericin B
  • Amphotericin B